

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2022 (29.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/272033 A8



(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 14/765 (2006.01)
C07K 14/725 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/034856

(22) International Filing Date:

24 June 2022 (24.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/214,963 25 June 2021 (25.06.2021) US
63/276,804 08 November 2021 (08.11.2021) US
63/328,603 07 April 2022 (07.04.2022) US

(71) Applicant: **HARPOON THERAPEUTICS, INC.**
[US/US]; 611 Gateway Boulevard, Suite 400, South San
Francisco, California 94080 (US).

(72) Inventors: **WESCHE, Holger**; 611 Gateway Boulevard,
Suite 400, South San Francisco, California 94080 (US).
LIN, Shuoyen Jack; 611 Gateway Boulevard, Suite 400,
South San Francisco, California 94080 (US). **KWANT,**
Kathryn; 611 Gateway Boulevard, Suite 400, South San

Francisco, California 94080 (US). **LEMON, Bryan D.**;
611 Gateway Boulevard, Suite 400, South San Francisco,
California 94080 (US). **AUSTIN, Richard J.**; 611 Gate-
way Boulevard, Suite 400, South San Francisco, California
94080 (US).

(74) Agent: **WANG, Yingjiao**; Wilson Sonsini, 650 Page Mill
Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

(54) Title: EXTENDED-RELEASE IMMUNE CELL ENGAGING PROTEINS AND METHODS OF TREATMENT

TriTAC XR

(57) Abstract: Provided herein is descriptions of extended-release im-
mune cell binding protein comprising a masking peptide and cleavable
linker, and the methods of using thereof. Also described is a pharma-
ceutical composition comprising a protein with a masking peptide and a
cleavable linker, and the method of using thereof.




FIG. 1A

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

16 February 2023 (16.02.2023)

(48) Date of publication of this corrected version:

21 December 2023 (21.12.2023)

(15) Information about Correction:

see Notice of 21 December 2023 (21.12.2023)